Anti-angiogenic therapy for VEGF or VEGF receptor-2 (VEGFR-2) can increase the transport of T cells to the tumor, thereby reducing immunosuppressive cytokines and T-regs, helping overcome resistance to the checkpoint inhibitors’ medicinal properties (30) (Figure 2). The gene discussed is VEGFA; the disease is neoplasm.